[A one-year prospective study of disodium etidronate versus 17 beta estradiol in the prevention of postmenopausal osteoporosis].

This prospective, controlled, nonrandomized, one-year trial in women included less than ten years after menopause was designed to compare the preventive efficacy on postmenopausal bone loss of replacement percutaneous 17 beta estradiol versus intermittent disodium etidronate. Twenty-five patients took oral disodium etidronate in a daily dosage of 200 mg in two-month courses separated by two-month intervals, with 1 g/day elemental calcium. Twenty-three patients used percutaneous 17 beta estradiol in daily dosage of 1.

[Fibroblastic rheumatism. A clinical and histological entity].

In 1980 was described for the first time a disease which seemed unknown until then. From that time three cases have been published. The current study summarizes their common characteristic, combining joint involvements to nodular-type involvements to systemic involvement, i.